These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9850093

  • 1. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.
    Lingen MW, Polverini PJ, Bouck NP.
    Cancer Res; 1998 Dec 01; 58(23):5551-8. PubMed ID: 9850093
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells.
    Lingen MW, Polverini PJ, Bouck NP.
    Lab Invest; 1996 Feb 01; 74(2):476-83. PubMed ID: 8780165
    [Abstract] [Full Text] [Related]

  • 3. Angiogenesis in oral cancer.
    Hasina R, Lingen MW.
    J Dent Educ; 2001 Nov 01; 65(11):1282-90. PubMed ID: 11765876
    [Abstract] [Full Text] [Related]

  • 4. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
    Riedel F, Götte K, Li M, Hörmann K, Grandis JR.
    Int J Oncol; 2003 Sep 01; 23(3):577-83. PubMed ID: 12888890
    [Abstract] [Full Text] [Related]

  • 5. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas.
    Benefield J, Petruzzelli GJ, Fowler S, Taitz A, Kalkanis J, Young MR.
    Invasion Metastasis; 1996 Sep 01; 16(6):291-301. PubMed ID: 9371228
    [Abstract] [Full Text] [Related]

  • 6. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
    Riedel F, Götte K, Hörmann K, Grandis JR.
    Adv Otorhinolaryngol; 2005 Sep 01; 62():103-20. PubMed ID: 15608422
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Nakamori S, Sakon M, Monden M.
    Oncol Rep; 2007 Oct 01; 18(4):801-9. PubMed ID: 17786339
    [Abstract] [Full Text] [Related]

  • 8. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4619-26. PubMed ID: 14555538
    [Abstract] [Full Text] [Related]

  • 9. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 10. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C.
    Clin Cancer Res; 2004 Dec 15; 10(24):8665-73. PubMed ID: 15623651
    [Abstract] [Full Text] [Related]

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 12. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM, Li J, Armstrong EA, Harari PM.
    Cancer Res; 2002 Aug 01; 62(15):4300-6. PubMed ID: 12154033
    [Abstract] [Full Text] [Related]

  • 13. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis.
    Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, Clayman GL.
    Cancer Res; 2005 Dec 15; 65(24):11501-9. PubMed ID: 16357159
    [Abstract] [Full Text] [Related]

  • 14. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B, Bran G, Hörmann K, Riedel F.
    Int J Oncol; 2009 Jan 15; 34(1):255-61. PubMed ID: 19082496
    [Abstract] [Full Text] [Related]

  • 15. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
    Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA.
    Cancer Res; 2001 Feb 15; 61(4):1477-85. PubMed ID: 11245454
    [Abstract] [Full Text] [Related]

  • 16. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G.
    Clin Cancer Res; 2000 Sep 15; 6(9):3739-47. PubMed ID: 10999768
    [Abstract] [Full Text] [Related]

  • 17. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
    Harada K, Supriatno, Yoshida H, Sato M.
    Int J Oncol; 2005 Dec 15; 27(6):1489-97. PubMed ID: 16273203
    [Abstract] [Full Text] [Related]

  • 18. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.
    Clin Cancer Res; 2001 Sep 15; 7(9):2840-53. PubMed ID: 11555602
    [Abstract] [Full Text] [Related]

  • 19. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
    Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR.
    Clin Cancer Res; 2002 Nov 15; 8(11):3570-8. PubMed ID: 12429648
    [Abstract] [Full Text] [Related]

  • 20. Effects of alpha-difluoromethylornithine and recombinant interferon-alpha 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice.
    Heston WD, Fleischmann J, Tackett RE, Ratliff TL.
    Cancer Res; 1984 Aug 15; 44(8):3220-5. PubMed ID: 6430546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.